BioCryst to Present at Upcoming Investor Conferences
06 nov. 2024 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 06, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences: 2024...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 nov. 2024 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
BioCryst Reports Third Quarter 2024 Financial Results and Provides Business Update
04 nov. 2024 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
— Q3 2024 ORLADEYO net revenue of $116.3 million (+35.7 percent y-o-y) — — Full-year 2024 ORLADEYO revenue guidance adjusted to $430-$435 million (top end of prior guidance range) — — Company...
BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)
24 oct. 2024 08h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world comparative research on the use of oral, once-daily...
BioCryst to Report Third Quarter 2024 Financial Results on November 4
21 oct. 2024 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2024 financial results on...
BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO® (berotralstat)
14 oct. 2024 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO®...
BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
10 oct. 2024 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
–Presentations will demonstrate high adherence and persistence, sustained attack reductions and patient preference for oral, once-daily ORLADEYO for hereditary angioedema– RESEARCH TRIANGLE PARK,...
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 oct. 2024 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted...
BioCryst Begins Enrollment in Phase 1 Trial Evaluating BCX17725, a KLK5 Inhibitor, for the Treatment of Netherton Syndrome
02 oct. 2024 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
—Potential best-in-class targeted treatment for Netherton syndrome is company’s first protein therapeutic to advance to the clinic— —Initial data from trial expected by end of 2025— RESEARCH...
U.S. Government Awards BioCryst $69 Million RAPIVAB® (peramivir injection) Contract for Strategic National Stockpile
30 sept. 2024 07h00 HE
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the U.S. Department of Health and Human Services (HHS) has awarded...